Intermountain Health has established the nation's first remote CAR-T cell collection site at St. George Regional Hospital, bringing advanced cancer treatment closer to patients in Southern Utah and Nevada.

Phesi's analysis of 167 million patient records reveals colorectal cancer has the largest volume of real-world data with nearly six million records, outpacing breast, lung, liver, and prostate cancers.

The FDA has granted orphan drug designation to LBL-034 for treating multiple myeloma, a rare and life-threatening cancer.

Moderna announced positive data from an early-stage study of its mRNA-based combination vaccine for COVID-19 and influenza, showing similar or stronger immune responses compared to standalone vaccines in older adults.

A real-world study of lorlatinib in ALK-rearranged non-small cell lung cancer demonstrated a median progression-free survival of 21.8 months, significantly higher than in previous trials.

KYV-101, an experimental cell therapy, has been granted orphan drug status by the European Medicines Agency for the treatment of myasthenia gravis (MG).

Trastuzumab deruxtecan (T-DXd) has demonstrated efficacy in patients with previously treated HER2-mutated non-small cell lung cancer (NSCLC).

Elicera Therapeutics reports that two out of three patients in the first cohort of the CARMA study achieved complete metabolic response with ELC-301, an iTANK-armed CD20-targeting CAR T-cell therapy.

Zanidatamab, a novel HER2-targeted bispecific antibody, demonstrated a 36.4% objective response rate and 86.4% disease control rate when combined with chemotherapy in heavily pretreated HER2-positive breast cancer patients.

A phase 1b trial investigated the combination of an oncolytic virus and nivolumab in patients with muscle-invasive bladder cancer.

Cilta-cel demonstrates significant survival benefits in multiple myeloma patients, even in late and early relapse scenarios.

Sanofi's amlitelimab (formerly KY1005), acquired through its $1.45 billion Kymab purchase, demonstrated significant efficacy in a Phase 2a trial for moderate to severe atopic dermatitis with an 80% improvement in EASI scores at the low dose.

Clinical research in the seven major markets (7MM) for Parkinson's disease (PD) is heavily focused on disease-modifying therapies (DMTs) to address unmet needs.

The PARSIFAL trial indicated no significant efficacy difference between palbociclib combined with fulvestrant versus letrozole, suggesting current practices of using CDK4/6 inhibitors with aromatase inhibitors remain valid.

The Federal Circuit has affirmed the Patent Trial and Appeal Board's decision invalidating two patents covering experimental gene therapy for hemophilia treatment, handing Pfizer a significant legal victory.

Eisai's Phase Ib trial of E7386 in combination with lenvatinib demonstrated a 30% overall response rate in advanced endometrial cancer patients who progressed after platinum-based chemotherapy and immunotherapy.

Dapirolizumab pegol (DZP) met its primary endpoint in the Phase 3 PHOENYCS GO trial, demonstrating statistically significant improvement in systemic lupus erythematosus (SLE) disease activity.

Johnson & Johnson has submitted applications to the FDA and EMA for Darzalex Faspro to treat high-risk smoldering multiple myeloma.

Puma Biotechnology has commenced the ALISCA-Breast1 Phase II trial to evaluate alisertib combined with endocrine therapy for HR+/HER2- metastatic breast cancer patients.

HSK21542, a novel kappa opioid receptor agonist, demonstrated statistically significant superiority over placebo in reducing postoperative pain intensity in two phase 3 trials involving 658 patients across 47 centers in China.